Preparation method of Pinefibrate
By optimizing the synthetic route of pemafibrate, using SMA and compound C as starting materials, controlling the reaction conditions, and avoiding column chromatography purification, the problems of low purity and high cost in existing technologies have been solved, and efficient industrial production has been achieved.
Patent Information
- Application Number
- CN202410928792.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-11
AI Technical Summary
Existing synthetic routes for pemabet have problems such as numerous byproduct impurities, low purity, high production costs, and unsuitability for industrial production.
Using SMA and compound C as starting materials, the reaction temperature, time and material ratio were controlled to avoid column chromatography purification. The synthetic route was optimized by using derivatives of compound E to reduce byproducts and improve purity and yield.
The synthesis of pemabet with high purity and high yield has been achieved, simplifying the post-processing, reducing production costs, and making it suitable for industrial production.
Smart Images

Figure CN118955420A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to a method for synthesizing Pemabate, wherein the chemical name of Pemabate is: (2R)-2-[-3(-{1,3-benzoxazol-2-yl[3(-4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butyric acid. Background Art
[0002] Pemafibrate is a new, highly selective PPARα modulator developed by Kowa Company. This drug binds to PPARα and regulates the expression of genes involved in lipid metabolism, thereby reducing triglyceride (TG) levels in the blood and increasing high-density lipoprotein cholesterol (HDL-C) levels. Related studies have shown that Pemafibrate has a significant effect on reducing fasting serum triglycerides, can enhance the effect of HDL-C, and this effect is long-lasting. Pemafibrate ordinary tablets are used to treat hyperlipidemia (including familial hyperlipidemia). Compared with Pemafibrate tablets, which need to be taken twice a day, the sustained-release tablets only need to be taken once a day. Pemafibrate is the world's first peroxisome proliferator-activated receptor α (PPARα) modulator that has obtained market approval. It can improve the problem of low serum triglyceride levels by regulating liver lipid metabolism, and its safety is better than other fibrate lipid-lowering drugs.
[0003]
[0004] At present, patent CN100425594C reports multiple synthetic routes, in which several key starting materials are derived from several decomposition fragments of the structure, as follows:
[0005]
[0006] Snippet breakdown:
[0007]
[0008] Many of these synthetic routes have been protected.
[0009] In addition, the preparation method of EP1852426A1 (European patent) is A+B+C+D+E, wherein all steps except step 1 are column chromatography purification, and the synthetic route is as follows:
[0010]
[0011] In this patent, the reaction of intermediate 2 in step 3 with compound C easily forms a double-substituted impurity X (accounting for more than 1%). At the same time, when intermediate 3 in step 4 reacts with compound D, there will inevitably be a coupling side reaction of hydroxyl and halogenated groups, resulting in a by-product residual impurity Z that is difficult to remove. It is brought into the subsequent steps. When intermediate 5 is an oily substance (not easy to refine and purify), it will directly cause the crude product to have low purity and affect the quality. Among them, the structural formulas of impurity X and impurity Z are as follows. Therefore, except for step 1, the entire preparation method requires column chromatography purification to improve the purity of the crude product. It is necessary to solve the problem of inevitably generating a large amount of solid waste and waste liquid when performing separation and purification by multiple silica gel column chromatography. The entire post-processing process is complicated and cumbersome, time-consuming, and has high production costs, which is not suitable for industrial large-scale production.
[0012] Summary of the invention
[0013] The purpose of the present invention is to provide a new method for preparing Pemabet based on the prior art.
[0014] The purpose of the present invention can be achieved by the following measures:
[0015] A method for preparing Pemabet, comprising the following steps:
[0016] (1) Compound SMA reacts with compound C to obtain intermediate 1;
[0017]
[0018] (2) reacting intermediate 1 with compound D, followed by reduction with potassium borohydride to obtain intermediate 2;
[0019]
[0020] (3) Intermediate 2 reacts with a derivative of compound E to obtain intermediate 3;
[0021]
[0022] (4) Intermediate 3 is hydrolyzed to obtain Pemabet;
[0023]
[0024] The preparation method of the present invention has the following synthetic route:
[0025]
[0026] In step (1), the molar ratio of SMA to compound C is 1:1.1 to 1:2. To obtain better effects, the molar ratio of SMA to compound C is 1:1.1 to 1.5. More preferably, the molar ratio of SMA to compound C is 1:1.2.
[0027] In the present invention, in step (1), the reaction temperature is 20 to 80°C, and more preferably the reaction temperature is 50 to 60°C.
[0028] In step (1), the reaction time is 20 to 40 hours, preferably 30 hours.
[0029] In step (1), SMA can be purchased directly, which is cheap and can significantly shorten the reaction route. In addition, in step (1), direct coupling with the halide of compound C can avoid the by-products in the original research literature, and there is no need to add protection and deprotection steps, which not only ensures the purity of the product, but also shortens the reaction route, providing a good reference for industrial production.
[0030] In step (2), the reaction of intermediate 1 with compound D is carried out at a temperature of 10 to 30°C, preferably 15 to 25°C, more preferably 20°C; and a reaction time of 20 to 40 hours, preferably 30 hours.
[0031] In step (2), the intermediate 1 reacts with the compound D, and the molar ratio of the intermediate 1 to the compound D is 1:1.1 to 1:2, preferably 1:1.1 to 1.5, and more preferably 1:1.2.
[0032] In step (3), the compound E derivative can be prepared by reacting compound E with trifluoromethanesulfonic anhydride;
[0033]
[0034] In step (3), the reaction conditions of compound E and trifluoromethanesulfonic anhydride are: the reaction temperature is -5 to 5°C, preferably 0°C; the molar ratio of compound E to trifluoromethanesulfonic anhydride is 1:0.8-1.2; preferably 1:1.0.
[0035] In step (3), the reaction of intermediate 2 with the derivative of compound E is carried out at a temperature of 10 to 30°C, preferably 15 to 25°C, more preferably 20°C; and a reaction time of 10 to 20 hours, preferably 14 hours.
[0036] Furthermore, the molar ratio of intermediate 2 to compound E is 1:0.5-0.9; preferably 1:0.7.
[0037] In step (4), the hydrolysis reaction conditions are: the reaction temperature is 10 to 30° C., preferably 15 to 25° C., more preferably 20° C.; the reaction time is 1 to 4 hours, and the base used for hydrolysis is sodium hydroxide.
[0038] Adopt the technical scheme of the present invention, the advantages are as follows:
[0039] The invention provides a novel preparation method of Pemabet, which takes SMA and compound C as starting materials, and strictly controls the reaction temperature, reaction time and material ratio, has high yield and purity of the product, few by-products, simple post-treatment process, does not require column chromatography purification, and is conducive to the subsequent preparation of high-quality finished products and impurity control. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 is the HPLC chart of intermediate 1 obtained in Example 1 of the present application;
[0041] Figure 2 This is the HPLC chart of the Pemabet intermediate 1 obtained in Comparative Example 1 of the present application;
[0042] Figure 3 is the HPLC chart of intermediate 2 obtained in Example 1 of the present application;
[0043] Figure 4 This is the HPLC chart of the Pemabet intermediate 2 obtained in Comparative Example 1 of this application
[0044] Figure 5 is the HPLC chart of Pemabet obtained in Example 1 of the present application;
[0045] Figure 6 is the HPLC chart of Pemabet obtained in Comparative Example 1 of the present application;
[0046] Figure 7 This is the MS confirmation chart of the intermediate 1N-(3-(4-methoxyphenoxy)propyl)benzo[d]oxazol-2-amine in Example 1 of the present application. DETAILED DESCRIPTION
[0047] The present invention is further explained below by specific examples and comparative examples, but this is not intended to limit the present invention. Professionals and technicians in this field can make any modifications, equivalent substitutions or improvements based on the basic ideas of the present invention, which should all be included in the scope of the present invention.
[0048] Example 1 The preparation method of Pemabet, the synthesis route of which is as follows:
[0049]
[0050] a) Preparation of Pemabet intermediate 1 (N-(3-(4-methoxyphenoxy)propyl)benzo[d]oxazol-2-amine)
[0051] Add 10.00g SMA and 40ml DMF to a 200ml three-necked bottle, add 3.87g triethylamine at 15-25℃, the solid is completely dissolved, heat to 50℃, add 10.1g 2-chlorobenzoxazole (compound C) to the resulting mixed solution, control the temperature at 50-60℃ and react for 30 hours, cool the resulting reaction solution to room temperature, add 40ml water, 100ml ethyl acetate, adjust the pH to 3-4 with hydrochloric acid, extract impurities, repeat once, add 100ml ethyl acetate to the resulting aqueous phase, adjust the pH to 8-10 with sodium hydroxide, extract the product, wash with water, dry with anhydrous sodium sulfate, concentrate under reduced pressure to obtain a block, recrystallize with 50ml isopropanol to obtain 15.03g of intermediate 1 solid, purity 99%, yield 91.33%. Among them, the MS confirming its structure is shown in Figure 7 The molecular weight of the compound is 298, the positive ion is 299, and the negative ion is 297, which is confirmed to be intermediate 1. The relevant chromatogram is shown in Figure 1 .
[0052] b) Preparation of Pemabet intermediate 2:
[0053] Add 15.00g of intermediate 1 and 50ml of methanol to a 500ml three-necked flask, stir and dissolve at 15-25°C, then dissolve 7.37g of compound D in 50ml of methanol, and dropwise add to the mixed solution at 20°C for 10 minutes. During the stirring process, react at 20°C for 30 hours. Then dropwise add sodium borohydride aqueous solution (2.1g dissolved in 100ml of water) at 20°C to the reaction solution obtained above for 20 minutes. After the addition is completed, stir at 20°C for 12 hours, filter and wash with water, and vacuum dry at 80°C for 5 hours to obtain 19.1g of yellow crystals with a purity of 99.52 and a yield of 93.43%. See the relevant chromatogram for details. Figure 3 .
[0054] c) Preparation of Pemabet intermediate 3
[0055] Preparation of n-butyl (S)-2-trifluoromethanesulfonyl hydroxybutyrate (compound E derivative): To a 50 ml three-necked flask, 0.3 g of (S)-2-hydroxybutyric acid n-butyl ester (compound E) and 5 ml of dichloromethane were added in sequence, stirred and dissolved, cooled to 0°C, 0.155 g of pyridine was added, and 0.528 g of trifluoromethanesulfonic anhydride was added dropwise under the condition of temperature control at 0°C. After the addition was completed, the mixture was stirred and reacted for 30 minutes. After the reaction was completed, the mixture was washed with water, the organic phase was collected, and dried by rotation. The obtained concentrate was chromatographically separated on an adsorption column filled with 30 g of 200-300 mesh silica gel. The eluent was dichloromethane in an amount of 300 ml to obtain a compound E derivative (n-butyl (S)-2-trifluoromethanesulfonyl hydroxybutyrate), which was dissolved in 10 ml of acetonitrile.
[0056] 0.53 g of intermediate 2 was added to 10 ml of acetonitrile, 0.272 g of potassium carbonate was added at 15-25° C., stirred for 10 minutes, the acetonitrile solution of n-butyl (S)-2-trifluoromethanesulfonylhydroxybutyrate prepared above was added, reacted at 15-25° C. for 14 hours, quenched with water, extracted with toluene, washed with brine, dried over sodium sulfate, filtered and concentrated, and purified to obtain 0.73 g of colorless oil, which was intermediate 3.
[0057] d) Preparation of Pemabet:
[0058] Add 0.68 g of intermediate 3 oil to a 50 ml three-necked reaction bottle, add 20 ml of ethanol to stir and dissolve, add 2 ml of 4N sodium hydroxide solution at 0°C, react at 15-25°C for 3 hours, remove ethanol under reduced pressure, add water, add concentrated hydrochloric acid under ice bath cooling to acidify, extract the product with ethyl acetate, wash with water, wash with brine, dry with anhydrous sodium sulfate, filter and concentrate, slurry with anhydrous ethanol, and filter to obtain 0.58 g of white solid with a purity of 99% and a yield of 95.4%. See the relevant chromatogram for details. Figure 5 .
[0059] Comparative Example 1: Preparation method of Pemabet, the synthesis route of which is as follows:
[0060]
[0061] (a) Add 10.00 g of SMA and 50 ml of methanol to a 500 ml three-necked flask, stir and dissolve at 15-25° C., dissolve 6.7 g of SMB in 50 ml of methanol, and dropwise add to the mixed solution at 20° C. for 5 minutes. React at 20° C. for 20 hours. Then dropwise add sodium borohydride aqueous solution (2.1 g dissolved in 100 ml of water) at 20° C. to the reaction solution obtained above for 5 minutes. After the dropwise addition is complete, stir at 20° C. for 12 hours, filter and wash with water, and vacuum dry at 80° C. for 5 hours to obtain 13.9 g of yellow crystals (3-[[3-(4-methoxyphenoxy)propyl]aminomethyl]phenol) with a purity of 96% and a yield of 87.4.0%. See the relevant chromatograms. Figure 2 .
[0062] (b) Add 1.0g 3-[[3-(4-methoxyphenoxy)propyl]aminomethyl]phenol and 4ml DMF to a 20ml three-necked flask, add 0.387g triethylamine at 15-25°C, stir until the solid is completely dissolved, heat the resulting mixed solution to 80°C, add 0.534g of compound SMC (2-chlorobenzoxazole) dropwise to the above mixed solution, control the temperature at 80°C to react for 4 hours, after the reaction is completed, cool the resulting reaction solution to 15-25°C, remove the solvent by distillation, add ethyl acetate to the extracted product, wash with water, wash with brine, dry with anhydrous sodium sulfate, and concentrate under reduced pressure to obtain an oily substance. Then mix the obtained oily substance with silica gel column, and purify it by column using a mixed solution of n-heptane and ethyl acetate in a volume ratio of 3:1 as the eluent to obtain 1.3g of white solid. Purity 97.86%, yield 92.3%. Related chromatograms are shown in Figure 4 .
[0063] c) Preparation of Pemabet intermediate 3
[0064] Preparation of n-butyl (S)-2-trifluoromethanesulfonyl hydroxybutyrate (compound E derivative): To a 50ml three-necked flask, 0.3g of (S)-2-hydroxybutyric acid n-butyl ester (compound E) and 5ml of dichloromethane were added in sequence, stirred and dissolved, cooled to 0°C, 0.155g of pyridine was added, and 0.528g of trifluoromethanesulfonic anhydride was added dropwise under the condition of temperature control at 0°C. After the addition was completed, the mixture was stirred and reacted for 30 minutes. After the reaction was completed, the mixture was washed with water, the organic phase was collected, and dried. The obtained concentrate was chromatographically separated on an adsorption column filled with 30g of 200-300 mesh silica gel. The eluent was dichloromethane in an amount of 300ml to obtain a compound E derivative (n-butyl (S)-2-trifluoromethanesulfonyl hydroxybutyrate), which was dissolved in 10ml of acetonitrile.
[0065] 0.53 g of intermediate 2 was added to 10 ml of acetonitrile, 0.272 g of potassium carbonate was added at 15-25° C., stirred for 10 minutes, the acetonitrile solution of n-butyl (S)-2-trifluoromethanesulfonylhydroxybutyrate prepared above was added, reacted at 15-25° C. for 14 hours, quenched with water, extracted with toluene, washed with brine, dried with sodium sulfate, filtered and concentrated to obtain 0.68 g of colorless oil, which is intermediate 3.
[0066] d) Preparation of Pemabet:
[0067] Add 0.68 g of intermediate 3 oil to a 50 ml three-necked reaction flask, add 20 ml of ethanol to stir and dissolve, add 2 ml of 4N sodium hydroxide solution at 0°C, react at 15-25°C for 3 hours, remove ethanol under reduced pressure, add water, add concentrated hydrochloric acid under ice bath cooling, extract the product with ethyl acetate, wash with water, wash with brine, dry with anhydrous sodium sulfate, filter and concentrate, purify to obtain 0.50 g of white solid, purity 96.1%, yield 82.6%. Related chromatograms are shown in Figure 6 .
[0068] The yield and purity of the intermediate 2 in the embodiment and the comparative example were determined by HPLC, as shown in Table 1 below:
[0069] Table 1 Comparative data of purity and impurity distribution of intermediate 2 in Example and Comparative Example 1
[0070]
[0071] It can be seen from the above results that the intermediate 2 prepared in the present invention has a high yield, good purity and less impurities than that in comparative example 1. It is of great help to the preparation of subsequent finished products and is easier to achieve industrial production of the target product.
[0072] Among them, the HPLC detection method is as follows:
[0073]
[0074]
[0075] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, a person skilled in the art should understand that it is still possible to modify the technical solutions described in the aforementioned embodiments, or to perform equivalent replacements on some of the technical features therein. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for preparing Pemabet, characterized in that It includes the following steps: (1) Compound SMA reacts with compound C to obtain intermediate 1; (2) reacting intermediate 1 with compound D, followed by reduction with sodium borohydride to obtain intermediate 2; (3) Intermediate 2 reacts with a derivative of compound E to obtain intermediate 3; (4) Intermediate 3 is hydrolyzed to obtain Pemabet; 2. The preparation method according to claim 1, characterized in that: In step (1), the molar ratio of compound SMA to compound C is 1:1.1 to 1:2, preferably 1:1.1 to 1.5, and more preferably 1:1.
2.
3. The preparation method according to claim 2, characterized in that: In step (1), the reaction temperature is 20 to 80° C., preferably 50 to 60° C.; the reaction time is 20 to 40 hours, preferably 30 hours.
4. The preparation method according to claim 1, characterized in that: In step (2), in the reaction between intermediate 1 and compound D, the molar ratio of intermediate 1 to compound D is 1:1.1 to 1:2, preferably 1:1.1 to 1.5, and more preferably 1:1.
2.
5. The preparation method according to claim 4, characterized in that: In step (2), the reaction of intermediate 1 with compound D is carried out at a temperature of 10 to 30°C, preferably 15 to 25°C, more preferably 20°C; and a reaction time of 20 to 40 hours, preferably 30 hours.
6. The preparation method according to claim 1, characterized in that: In step (3), the compound E derivative is prepared by reacting compound E with trifluoromethanesulfonic anhydride; 7. The preparation method according to claim 6, characterized in that: In step (3), the reaction conditions of compound E and trifluoromethanesulfonic anhydride are: the reaction temperature is -5 to 5°C, preferably 0°C; the molar ratio of compound E to trifluoromethanesulfonic anhydride is 1:0.8-1.2; preferably 1:1.
0.
8. The preparation method according to claim 7, characterized in that: In step (3), the reaction of intermediate 2 with the derivative of compound E is carried out at a temperature of 10 to 30°C, preferably 15 to 25°C, more preferably 20°C; and a reaction time of 10 to 20 hours, preferably 14 hours.
9. The preparation method according to claim 8, characterized in that: In step (3), the molar ratio of intermediate 2 to compound E is 1:0.5-0.9; preferably 1:0.
7.
10. The preparation method according to claim 1, characterized in that: In step (4), the hydrolysis reaction conditions are: the reaction temperature is 10 to 30° C., preferably 15 to 25° C., more preferably 20° C.; the reaction time is 1 to 4 hours, preferably 3 hours, and the base used for hydrolysis is sodium hydroxide.
Citation Information
Patent Citations
Refining method of 3-[[2-benzoxazolyl [3-(4-methoxyphenoxy) propyl] amino] methyl] phenol
CN116462638A
Process For Production of Optically Active Ppar-Activating Compound and Intermediate of the Same
US20080194833A1
A process for the preparation of pemafibrate and intermediates thereof
WO2024201358A1
Cited By
Method for preparing chiral butyrate units using enzymatic kinetic resolution and method for converting them to pemafibrate.
JP2026169468A
